Le Lézard
Classified in: Health, Science and technology
Subject: SHM

SOPHiA GENETICS Publishes Results of 2022 Annual General Meeting

BOSTON and LAUSANNE, Switzerland, June 15, 2022 /CNW/ -- SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00 p.m. CET (8:00 a.m. EDT).

The Company's shareholders approved each agenda item presented at the Meeting. The Meeting minutes and detailed voting results by agenda item have been published on the Company's website in the investor section. The detailed voting results will also be filed with the U.S. Securities and Exchange Commission on a Report on Form 6-K.

Additionally, the Company would like to welcome the newly appointed director, Jean-Michel Cosséry to its Board of Directors. Mr. Cosséry will be a strong addition to the Board of Directors as he offers more than 25-years of industry experience. The Company looks forward to Mr. Cosséry's future contributions.

The Company would also like to thank all shareholders represented or having voted by mail for their valued commitment and support.


SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDMtm Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDMtm Platform and related solutions, products and services are currently used by over 790 hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram. Where others see data, we see answers.

SOPHiA GENETICS Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.


These press releases may also interest you

at 00:15
The pharmaceutical contract research and manufacturing (CRAM) market size is forecast to increase by USD 121.35 billion from 2022 to 2027, at a CAGR of 10.32%, according to the recent market study by Technavio. The growth of the market depends on...

at 00:12
On June 8th, 2023, Coviccine® Trivalent XBB.1.5-Recombinant COVID-19 Trivalent (XBB.1.5+BA.5+Delta) Protein Vaccine (Sf9 cell) developed by WestVac Biopharma/ West China Medical Center, Sichuan University was approved for EUA by relevant authorities...

at 00:01
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the submission of a New Drug Application (NDA) on June 9, 2023 to Japan's Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab, a first-in-class...

8 jun 2023
Mind Cure Health Inc. (FRA: 6MH) ("Mind Cure", the "Company" or the "Resulting Issuer" following the completion of the Proposed Transaction (as defined below)) and LNG Energy Group Inc. ("LNG Energy") are pleased to provide an update on the...

8 jun 2023
On 8 June 2023, the 2023 Fosun International Investor Open Day was held in Shanghai. It was the first time that Fosun International had held a large-scale offline open day after the pandemic. More than 100 domestic and foreign investor...

8 jun 2023
Elevation Oncology, Inc. , an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the pricing of an...

News published on and distributed by: